Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT05641012 Not yet recruiting - Metastatic Melanoma Clinical Trials

Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma

Helioma
Start date: December 1, 2022
Phase:
Study type: Observational

Melanoma is one of the most aggressive forms of skin cancer, representing only 5% of all skin cancer but 80% of all death by skin cancer. Diagnosis and treatment of melanoma must be early because prognosis depends on stage disease. Immunotherapy is used in metastatic melanoma. However, all patients not respond to immunotherapy. Helioderma (photoaging) is a marker of exposure to UV rays and therefore of mutagenesis. Thus, helioderma could be associated with the response to immunotherapy.

NCT ID: NCT05640193 Active, not recruiting - Metastatic Melanoma Clinical Trials

A Study of LN-144 in People With Metastatic Melanoma to the Brain

Start date: November 25, 2022
Phase: Phase 1
Study type: Interventional

This is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.

NCT ID: NCT05629546 Not yet recruiting - Metastatic Melanoma Clinical Trials

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Start date: June 30, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML NK cells from either an autologous source or allogeneic source are safe and tolerable in subjects with advanced and/or metastatic melanoma.

NCT ID: NCT05628883 Recruiting - Metastatic Melanoma Clinical Trials

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Start date: November 22, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this first in human study is to evaluate the feasibility, safety, and efficacy of administering TBio-4101 (tumor infiltrating lymphocytes [TIL]) after receiving a lymphodepleting chemotherapy regimen and before receiving interleukin-2 (IL-2) in participants with unresectable or metastatic melanoma.

NCT ID: NCT05625399 Recruiting - Melanoma Clinical Trials

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

RELATIVITY-127
Start date: March 6, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.

NCT ID: NCT05621837 Recruiting - Breast Cancer Clinical Trials

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Serpentine
Start date: March 10, 2022
Phase:
Study type: Observational

The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.

NCT ID: NCT05620290 Recruiting - Melanoma Clinical Trials

MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer

Start date: June 15, 2022
Phase: Phase 1
Study type: Interventional

The objective of this study is to examine the safety profile and therapeutic efficacy of MRI-guided focused ultrasound microbubble therapy and radiotherapy in humans.

NCT ID: NCT05620134 Recruiting - Cancer Clinical Trials

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Start date: October 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.

NCT ID: NCT05615883 Recruiting - Melanoma Clinical Trials

Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients

Agility
Start date: January 20, 2020
Phase: N/A
Study type: Interventional

This study is designed to investigate the effects of ketogenic milieu induced by acute exercise as well as the effects of recurrent exercise bouts on functional status and the accumulation in peripheral blood of MDSCs and the consequent balance on antitumor immunity in melanoma patients.

NCT ID: NCT05611229 Completed - Metastatic Melanoma Clinical Trials

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Start date: June 16, 2020
Phase:
Study type: Observational

This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.